Aggressive Non-Hodgkin Lymphoma: Predictive Value Of Sarcopenia and Skeletal Muscle Density On Prognosis With Rituximab Containing Therapy

Sarcopenia is an established adverse risk factor for solid organ malignancies. Recent evidence suggests sarcopenia predicts a poor prognosis in elderly patients with diffuse large B-cell lymphoma (DLBCL) independent of Revised International Prognostic Index (R-IPI) scores. Because of the focus on an...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2013-11, Vol.122 (21), p.3023-3023
Main Authors: Chu, Michael P, Lieffers, Jessica, Belch, Andrew R, Chua, Neil, Fontaine, Amelie, Sangha, Randeep, Turner, A. Robert, Ghosh, Sunita, Sawyer, Michael
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sarcopenia is an established adverse risk factor for solid organ malignancies. Recent evidence suggests sarcopenia predicts a poor prognosis in elderly patients with diffuse large B-cell lymphoma (DLBCL) independent of Revised International Prognostic Index (R-IPI) scores. Because of the focus on an elderly population, it is difficult to generalize to the DLBCL population as a whole. Newer evidence suggests low skeletal muscle density (SMD) is a more significant indicator of poor prognosis in renal cell carcinoma and melanoma than sarcopenia. SMD can be approximated using computed tomography (CT) images and measuring muscle radiation attenuation in Hounsfield Units (HU). An average muscle SMD of
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V122.21.3023.3023